首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal CD28 Antibody

  • 中文名: CD28抗体
  • 别    名: Tp44
货号: IPD32456
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 1/500-1/2000 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesTp44
Entrez GeneID940
clone3E7H3
WB Predicted band size25kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human PLBD1
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

参考文献

以下是关于CD28抗体的3篇代表性文献,涵盖基础机制、治疗应用及临床案例:

---

1. **文献名称**: *Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412*

**作者**: Suntharalingam, G. et al.

**摘要**: 该文献报告了抗CD28超激动剂抗体TGN1412的I期临床试验结果。6名健康受试者在给药后出现严重的细胞因子风暴,导致多器官衰竭。研究揭示了CD28超激动剂抗体在强效激活T细胞(尤其是调节性T细胞)的同时可能引发不可控的免疫反应,强调了此类抗体在临床设计中的风险。

---

2. **文献名称**: *CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation*

**作者**: Lenschow, D.J. et al.

**摘要**: 通过体外使用抗CD28抗体阻断或增强共刺激信号,研究发现CD28通路显著增强T细胞活化和增殖,而CTLA-4则起抑制作用。该研究奠定了CD28作为关键共刺激受体的理论基础,并为后续抗体疗法开发提供了依据。

---

3. **文献名称**: *Superagonistic Anti-CD28 Antibodies: Unique Activators of Regulatory T Cells*

**作者**: Hünig, T. et al.

**摘要**: 研究发现某些抗CD28单克隆抗体(如超激动剂抗体)能够选择性激活调节性T细胞(Tregs),而非效应T细胞。这种特性被探索用于自身免疫性疾病的治疗,例如在多发性硬化模型中通过增强Treg功能抑制炎症反应。

---

**备注**:CD28抗体的研究涵盖激动剂(如TGN1412)和拮抗剂(如用于抑制移植排斥)两种方向。后续研究更注重抗体设计的安全性,例如开发仅结合特定表位或联合其他靶点的双特异性抗体。

背景信息

CD28 is a critical co-stimulatory receptor expressed on T cells, playing a pivotal role in adaptive immune responses. Upon binding to CD80/CD86 ligands on antigen-presenting cells (APCs), CD28 synergizes with T cell receptor (TCR) signaling to amplify T cell activation, survival, and cytokine production. This "second signal" mechanism ensures proper immune activation while preventing anergy.

CD28-targeting antibodies have been explored therapeutically to modulate immune responses. Agonistic anti-CD28 antibodies were initially investigated to enhance T cell activation in cancer immunotherapy or immunodeficiency. However, a notorious clinical trial in 2006 (TGN1412. a super-agonistic anti-CD28 antibody) caused severe cytokine storms in healthy volunteers due to uncontrolled systemic T cell activation, highlighting the risks of excessive immune stimulation.

Conversely, antagonistic anti-CD28 antibodies or fusion proteins blocking CD28-CD80/86 interactions have shown promise in autoimmune diseases and transplantation by inhibiting pathogenic T cell responses. For example, abatacept (CTLA4-Ig), which blocks CD28 co-stimulation, is approved for rheumatoid arthritis. Recent research also explores CD28 modulation in CAR-T cell therapies to improve persistence and reduce exhaustion. Additionally, selective CD28 antagonists are being developed to minimize immunosuppressive side effects compared to broad-spectrum therapies.

The dual role of CD28 in immune activation and regulation continues to drive therapeutic innovation, emphasizing the need for precise targeting strategies to balance efficacy and safety.

客户数据及评论

折叠内容

大包装询价

×